KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Finished Goods (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 10 years of Finished Goods data on record, last reported at $26.0 million in Q4 2025.

  • For Q4 2025, Finished Goods rose 26.84% year-over-year to $26.0 million; the TTM value through Dec 2025 reached $26.0 million, up 26.84%, while the annual FY2025 figure was $26.0 million, 26.84% up from the prior year.
  • Finished Goods reached $26.0 million in Q4 2025 per ACAD's latest filing, up from $25.0 million in the prior quarter.
  • Across five years, Finished Goods topped out at $26.0 million in Q4 2025 and bottomed at $947000.0 in Q1 2021.
  • Average Finished Goods over 5 years is $9.5 million, with a median of $3.5 million recorded in 2021.
  • Peak YoY movement for Finished Goods: crashed 60.92% in 2021, then skyrocketed 758.53% in 2024.
  • A 5-year view of Finished Goods shows it stood at $1.1 million in 2021, then skyrocketed by 72.89% to $1.9 million in 2022, then soared by 159.66% to $5.0 million in 2023, then skyrocketed by 309.14% to $20.5 million in 2024, then grew by 26.84% to $26.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $26.0 million in Q4 2025, $25.0 million in Q3 2025, and $23.4 million in Q2 2025.